| Literature DB >> 32746843 |
Ruth F Hunter1, Jennifer M Murray2, Helen G Coleman3.
Abstract
BACKGROUND: Evidence is suggestive of sedentary behaviour being associated with an increased risk of endometrial cancer, but the evidence base is too limited to draw any conclusions for other cancers. The aim of the study was to investigate the association between recreational screen time and site-specific cancer risk.Entities:
Keywords: Cancer; Cohort study; Epidemiology; Screen time; Sedentary behaviour
Mesh:
Year: 2020 PMID: 32746843 PMCID: PMC7398067 DOI: 10.1186/s12966-020-00997-6
Source DB: PubMed Journal: Int J Behav Nutr Phys Act ISSN: 1479-5868 Impact factor: 6.457
Results of Cox proportional hazards analyses investigating the association between self-report daily TV viewing time and cancer incidence
| 1 h increase in TV viewing time | ≤1 h | 1- ≤ 3 h (reference) | 3- ≤ 5 h | > 5 h | |||
|---|---|---|---|---|---|---|---|
| Person-years | 3,526,324 | 736,537 | 1,781,542 | 818,674 | 189,571 | ||
| Skin, melanoma | Cases | 1635 | 315 | 831 | 404 | 85 | |
| HR (95% CI)* | 0.98 (0.95 1.01) | 0.24** | 0.99 (0.87 1.12) | 1.00 | 0.96 (0.85 1.08) | 0.84 (0.67 1.06) | |
| HR (95% CI)† | 1.01 (0.97 1.04) | 0.74 | 0.99 (0.87 1.13) | 1.00 | 1.004 (0.89 1.14) | 1.01 (0.80 1.29) | |
| HR (95% CI)a | 1.004 (0.97 1.04) | 0.84 | 1.01 (0.88 1.15) | 1.00 | 1.001 (0.88 1.13) | 1.02 (0.81 1.30) | |
| Oropharyngeal | Cases | 557 | 86 | 263 | 148 | 60 | |
| HR (95% CI)* | 0.83 (0.65 1.06) | 1.00 | 1.17 (0.96 1.43) | ||||
| HR (95% CI)† | 0.83 (0.64 1.07) | 1.00 | 1.07 (0.87 1.32) | ||||
| HR (95% CI) | 0.83 (0.64 1.07) | 1.00 | 1.07 (0.87 1.32) | ||||
| Lung | Cases | 2076 | 236 | 901 | 656 | 283 | |
| HR (95% CI)* | |||||||
| HR (95% CI)† | 1.02 (0.995 1.04) | 0.12** | 0.87 (0.75 1.01) | 1.00 | 0.98 (0.88 1.09) | 1.09 (0.93 1.26) | |
| HR (95% CI)h | 1.02 (0.997 1.05) | 0.09** | 1.00 | 0.98 (0.88 1.09) | 1.09 (0.94 1.27) | ||
| Breast (female only) | Cases | 5702 | 1097 | 2903 | 1386 | 316 | |
| HR (95% CI)* | 1.01 (0.99 1.02) | 0.43 | 0.93 (0.87 1.002) | 1.00 | 0.97 (0.91 1.03) | 1.003 (0.89 1.13) | |
| HR (95% CI)† | 1.003 (0.98 1.02) | 0.77** | 0.94 (0.88 1.01) | 1.00 | 0.96 (0.90 1.03) | 0.99 (0.87 1.12) | |
| HR (95% CI)b, h | 1.01 (0.99 1.03) | 0.59** | 1.00 | 0.95 (0.88 1.02) | 1.01 (0.87 1.16) | ||
| Uterus | Cases | 872 | 151 | 411 | 264 | 46 | |
| HR (95% CI)* | 1.04 (0.999 1.08) | 0.053 | 0.97 (0.81 1.17) | 1.00 | 0.95 (0.70 1.28) | ||
| HR (95% CI)† | 0.97 (0.93 1.02) | 0.21 | 1.05 (0.86 1.27) | 1.00 | 1.05 (0.89 1.24) | ||
| HR (95% CI)c | 0.97 (0.93 1.02) | 0.24 | 1.03 (0.84 1.27) | 1.00 | 1.04 (0.87 1.24) | ||
| Ovary | Cases | 578 | 105 | 287 | 155 | 31 | |
| HR (95% CI)* | 1.002 (0.95 1.05) | 0.93 | 0.95 (0.76 1.19) | 1.00 | 1.02 (0.84 1.24) | 0.91 (0.63 1.32) | |
| HR (95% CI)† | 1.02 (0.96 1.08) | 0.53 | 0.90 (0.71 1.15) | 1.00 | 1.04 (0.84 1.27) | 0.93 (0.63 1.38) | |
| HR (95% CI) | 1.02 (0.96 1.08) | 0.53 | 0.90 (0.71 1.15) | 1.00 | 1.04 (0.84 1.27) | 0.93 (0.63 1.38) | |
| Prostate | Cases | 5979 | 1116 | 2957 | 1562 | 344 | |
| HR (95% CI)* | 1.00 | 0.96 (0.90 1.02) | |||||
| HR (95% CI)† | 0.99 (0.97 1.004) | 0.12** | 1.05 (0.98 1.13) | 1.00 | 1.01 (0.94 1.07) | 0.94 (0.83 1.06) | |
| HR (95% CI)h | 0.99 (0.97 1.01) | 0.17** | 1.04 (0.97 1.12) | 1.00 | 1.01 (0.95 1.08) | 0.95 (0.84 1.07) | |
| Oesophagus | Cases | 541 | 70 | 246 | 176 | 49 | |
| HR (95% CI)* | 0.80 (0.61 1.04) | 1.00 | 1.30 (1.07 1.58) | 1.44 (1.06 1.96) | |||
| HR (95% CI)† | 1.03 (0.98 1.08) | 0.31** | 0.85 (0.64 1.13) | 1.00 | 1.09 (0.89 1.34) | 1.02 (0.73 1.42) | |
| HR (95% CI)f | 1.02 (0.97 1.08) | 0.34** | 0.86 (0.65 1.14) | 1.00 | 1.09 (0.88 1.34) | 1.02 (0.73 1.42) | |
| Stomach | Cases | 356 | 36 | 164 | 121 | 35 | |
| HR (95% CI)* | 1.00 | ||||||
| HR (95% CI)† | 1.00 | 1.12 (0.87 1.44) | 1.03 (0.69 1.53) | ||||
| HR (95% CI) | 1.00 | 1.12 (0.87 1.44) | 1.03 (0.69 1.53) | ||||
| Oesophagus and stomach | Cases | 891 | 105 | 405 | 297 | 84 | |
| HR (95% CI)* | 1.00 | ||||||
| HR (95% CI)† | 1.00 | 1.12 (0.95 1.31) | 1.04 (0.81 1.34) | ||||
| HR (95% CI) | 1.00 | 1.12 (0.95 1.31) | 1.04 (0.81 1.34) | ||||
| Hepatobiliary tract | Cases | 456 | 74 | 203 | 130 | 49 | |
| HR (95% CI)* | 1.02 (0.78 1.33) | 1.00 | 1.15 (0.93 1.44) | ||||
| HR (95% CI)† | 1.01 (0.96 1.07) | 0.62 | 1.08 (0.82 1.43) | 1.00 | 0.98 (0.78 1.24) | 1.26 (0.90 1.77) | |
| HR (95% CI) | 1.01 (0.96 1.07) | 0.62 | 1.08 (0.82 1.43) | 1.00 | 0.98 (0.78 1.24) | 1.26 (0.90 1.77) | |
| Pancreatic | Cases | 615 | 97 | 283 | 187 | 48 | |
| HR (95% CI)* | 0.96 (0.76 1.21) | 1.00 | 1.19 (0.99 1.43) | 1.25 (0.92 1.70) | |||
| HR (95% CI)† | 1.04 (0.99 1.09) | 0.15 | 0.99 (0.78 1.27) | 1.00 | 1.12 (0.92 1.36) | 1.07 (0.77 1.49) | |
| HR (95% CI)d | 1.03 (0.98 1.08) | 0.20 | 0.996 (0.78 1.27) | 1.00 | 1.11 (0.92 1.36) | 1.03 (0.74 1.44) | |
| Kidney | Cases | 779 | 113 | 390 | 206 | 70 | |
| HR (95% CI)* | 1.00 | 0.99 (0.83 1.17) | |||||
| HR (95% CI)† | 0.996 (0.95 1.04) | 0.86** | 0.92 (0.74 1.14) | 1.00 | 0.88 (0.74 1.05) | 1.08 (0.82 1.42) | |
| HR (95% CI) | 0.996 (0.95 1.04) | 0.86** | 0.92 (0.74 1.14) | 1.00 | 0.88 (0.74 1.05) | 1.08 (0.82 1.42) | |
| Bladder | Cases | 677 | 92 | 295 | 221 | 69 | |
| HR (95% CI)* | 0.90 (0.71 1.14) | 1.00 | |||||
| HR (95% CI)† | 1.04 (0.99 1.09) | 0.13** | 1.04 (0.81 1.32) | 1.00 | 1.29 (0.97 1.73) | ||
| HR (95% CI) | 1.04 (0.99 1.09) | 0.13** | 1.04 (0.81 1.32) | 1.00 | 1.29 (0.97 1.73) | ||
| Colorectal | Cases | 3358 | 538 | 1643 | 936 | 241 | |
| HR (95% CI)* | 1.00 | 1.05 (0.97 1.14) | 1.11 (0.97 1.28) | ||||
| HR (95% CI)† | 1.02 (0.999 1.04) | 0.07** | 0.93 (0.84 1.03) | 1.00 | 1.03 (0.94 1.12) | 1.05 (0.90 1.22) | |
| HR (95% CI)e, g, f (males) | 1.02 (0.995 1.04) | 0.93 (0.83 1.03) | 1.00 | 1.02 (0.93 1.11) | 1.03 (0.88 1.20) | ||
| Colon | Cases | 2155 | 329 | 1041 | 614 | 171 | |
| HR (95% CI)* | 1.00 | ||||||
| HR (95% CI)† | 0.92 (0.81 1.05) | 1.00 | 1.05 (0.94 1.17) | ||||
| HR (95% CI)e, g, f (males) | 0.93 (0.81 1.06) | 1.00 | 1.05 (0.94 1.16) | 1.17 (0.98 1.41) | |||
| Rectum | Cases | 1127 | 196 | 556 | 307 | 68 | |
| HR (95% CI)* | 1.01 (0.98 1.05) | 0.53** | 0.96 (0.81 1.13) | 1.00 | 1.04 (0.90 1.20) | 0.94 (0.73121) | |
| HR (95% CI)† | 0.996 (0.96 1.04) | 0.84** | 0.98 (0.82 1.16) | 1.00 | 1.04 (0.89 1.20) | 0.84 (0.63 1.11) | |
| HR (95% CI)e, g | 0.99 (0.95 1.03) | 0.67 | 0.96 (0.81 1.14) | 1.00 | 1.01 (0.87 1.18) | 0.82 (0.62 1.10) | |
| Brain tumours | Cases | 463 | 82 | 237 | 114 | 30 | |
| HR (95% CI)* | 1.03 (0.98 1.08) | 0.29 | 0.92 (0.72 1.19) | 1.00 | 0.93 (0.74 1.16) | 1.003 (0.69 1.47) | |
| HR (95% CI)† | 1.04 (0.98 1.10) | 0.20 | 0.87 (0.66 1.13) | 1.00 | 0.92 (0.73 1.17) | 0.96 (0.63 1.46) | |
| HR (95% CI) | 1.04 (0.98 1.10) | 0.20 | 0.87 (0.66 1.13) | 1.00 | 0.92 (0.73 1.17) | 0.96 (0.63 1.46) | |
| Thyroid | Cases | 242 | 48 | 124 | 57 | 13 | |
| HR (95% CI)* | 0.99 (0.91 1.07) | 0.75 | 0.95 (0.68 1.32) | 1.00 | 0.97 (0.70 1.33) | 0.97 (0.55 1.73) | |
| HR (95% CI)† | 1.001 (0.92 1.09) | 0.98 | 0.92 (0.65 1.30) | 1.00 | 0.93 (0.66 1.32) | 1.14 (0.63 2.06) | |
| HR (95% CI) | 1.001 (0.92 1.09) | 0.98 | 0.92 (0.65 1.30) | 1.00 | 0.93 (0.66 1.32) | 1.14 (0.63 2.06) | |
| Haematological malignancies | Cases | 2468 | 438 | 1208 | 652 | 170 | |
| HR (95% CI)* | 1.01 (0.98 1.03) | 0.52 | 0.995 (0.89 1.11) | 1.00 | 0.99 (0.90 1.09) | 1.06 (0.91 1.25) | |
| HR (95% CI)† | 1.002 (0.98 1.03) | 0.89 | 0.97 (0.87 1.09) | 1.00 | 0.97 (0.88 1.08) | 0.97 (0.82 1.16) | |
| HR (95% CI) | 1.002 (0.98 1.03) | 0.89 | 0.97 (0.87 1.09) | 1.00 | 0.97 (0.88 1.08) | 0.97 (0.82 1.16) | |
| Non-Hodgkin’s lymphoma | Cases | 1193 | 197 | 586 | 337 | 73 | |
| HR (95% CI)* | 1.01 (0.98 1.05) | 0.44 | 0.92 (0.78 1.08) | 1.00 | 1.06 (0.93 1.21) | 0.95 (0.74 1.21) | |
| HR (95% CI)† | 1.01 (0.98 1.05) | 0.48 | 0.89 (0.75 1.05) | 1.00 | 1.08 (0.93 1.24) | 0.85 (0.65 1.11) | |
| HR (95% CI) | 1.01 (0.98 1.05) | 0.48 | 0.89 (0.75 1.05) | 1.00 | 1.08 (0.93 1.24) | 0.85 (0.65 1.11) |
*Models adjusted for age and sex (total observations = 470,578)
†Models adjusted for age, sex, ethnicity (white/other), deprivation index (quintiles), education (University degree, A-levels/HNC/HND/NVQ, GCSE/O-level/CSE, OTHER, None), fruit and vegetable intake (< 5 portions/day, ≥5 portions/day), BMI (kg/m2), height (m), smoking status (never, former light smoker [< 20 pack-years], former heavy smoker [≥20 pack-years], current light smoker [< 20 pack-years], current heavy smoker [≥20 pack-years]) and alcohol intake (never, former, current [
aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
gResults for males and females combined using meta-analysis as covariates are different
hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
**Schoenfeld test indicated potential violation of the proportional hazards assumption (p < 0.05)
Results of Cox proportional hazards analyses investigating the association between self-report daily total screen time and cancer incidence
| 1 h increase in total screen time | ≤1 h | 1- ≤ 4 h (reference) | 4- ≤ 8 h | > 8 h | |||
|---|---|---|---|---|---|---|---|
| Person-years | 3,474,425 | 254,147 | 2,111,765 | 997,699 | 110,815 | ||
| Skin, melanoma | Cases | 1614 | 101 | 960 | 504 | 49 | |
| HR (95% CI)* | 0.99 (0.97 1.02) | 0.64** | 0.93 (0.76 1.14) | 1.00 | 1.02 (0.91 1.13) | 0.98 (0.73 1.30) | |
| HR (95% CI)† | 1.01 (0.98 1.03) | 0.62 | 0.97 (0.78 1.19) | 1.00 | 1.07 (0.96 1.20) | 1.06 (0.78 1.44) | |
| HR (95% CI)a | 1.01 (0.98 1.03) | 0.70 | 0.99 (0.80 1.22) | 1.00 | 1.07 (0.95 1.19) | 1.07 (0.79 1.45) | |
| Oropharyngeal | Cases | 552 | 24 | 312 | 191 | 25 | |
| HR (95% CI)* | 0.69 (0.46 1.05) | 1.00 | 1.18 (0.99 1.42) | 1.39 (0.92 2.09) | |||
| HR (95% CI)† | 1.02 (0.98 1.06) | 0.41 | 0.69 (0.45 1.04) | 1.00 | 1.10 (0.91 1.32) | 1.09 (0.71 1.67) | |
| HR (95% CI) | 1.02 (0.98 1.06) | 0.41 | 0.69 (0.45 1.04) | 1.00 | 1.10 (0.91 1.32) | 1.09 (0.71 1.67) | |
| Lung | Cases | 2014 | 119 | 995 | 774 | 126 | |
| HR (95% CI)* | 1.13 (0.93 1.37) | 1.00 | |||||
| HR (95% CI)† | 1.13 (0.92 1.38) | 1.00 | 1.05 (0.95 1.16) | ||||
| HR (95% CI)h | 1.12 (0.91 1.37) | 1.05 (0.95 1.16) | |||||
| Breast (female only) | Cases | 5609 | 418 | 3526 | 1522 | 143 | |
| HR (95% CI)* | 1.01 (0.996 1.02) | 0.16** | 0.91 (0.82 1.004) | 1.00 | 0.97 (0.92 1.04) | 1.08 (0.91 1.27) | |
| HR (95% CI)† | 1.003 (0.99 1.02) | 0.64** | 0.94 (0.85 1.04) | 1.00 | 0.95 (0.90 1.02) | 1.08 (0.91 1.29) | |
| HR (95% CI)b, h | 1.01 (0.99 1.02) | 0.37** | 0.93 (0.83 1.04) | 1.00 | 0.97 (0.90 1.04) | 1.11 (0.92 1.34) | |
| Uterus | Cases | 856 | 70 | 504 | 264 | 18 | |
| HR (95% CI)* | 1.03 (0.99 1.06) | 0.14 | 1.11 (0.87 1.43) | 1.00 | 1.12 (0.96 1.30) | 0.99 (0.62 1.58) | |
| HR (95% CI)† | 0.97 (0.93 1.004) | 0.08 | 1.15 (0.88 1.50) | 1.00 | 0.93 (0.80 1.09) | ||
| HR (95% CI)c | 0.97 (0.94 1.01) | 0.17 | 1.16 (0.89 1.53) | 1.00 | 0.93 (0.79 1.09) | 0.66 (0.38 1.12) | |
| Ovary | Cases | 561 | 44 | 354 | 149 | 14 | |
| HR (95% CI)* | 0.99 (0.95 1.04) | 0.75 | 0.99 (0.72 1.35) | 1.00 | 0.90 (0.74 1.09) | 1.08 (0.63 1.85) | |
| HR (95% CI)† | 0.997 (0.95 1.04) | 0.91 | 0.98 (0.71 1.35) | 1.00 | 0.90 (0.74 1.11) | 1.14 (0.66 1.95) | |
| HR (95% CI) | 0.997 (0.95 1.04) | 0.91 | 0.98 (0.71 1.35) | 1.00 | 0.90 (0.74 1.11) | 1.14 (0.66 1.95) | |
| Prostate | Cases | 5898 | 335 | 3340 | 2032 | 191 | |
| HR (95% CI)* | 1.07 (0.95 1.19) | 1.00 | 0.96 (0.91 1.01) | ||||
| HR (95% CI)† | 0.99 (0.98 1.004) | 0.16** | 1.06 (0.94 1.19) | 1.00 | 1.01 (0.95 1.07) | 0.94 (0.81 1.10) | |
| HR (95% CI)h | 0.99 (0.98 1.005) | 0.21** | 1.05 (0.93 1.18) | 1.00 | 1.01 (0.95 1.07) | 0.94 (0.81 1.10) | |
| Oesophagus | Cases | 528 | 28 | 272 | 216 | 12 | |
| HR (95% CI)* | 1.02 (0.69 1.50) | 1.00 | 0.75 (0.42 1.34) | ||||
| HR (95% CI)† | 1.003 (0.96 1.05) | 0.89 | 1.13 (0.77 1.68) | 1.00 | 1.13 (0.94 1.36) | ||
| HR (95% CI)f | 1.001 (0.96 1.04) | 0.95 | 1.15 (0.77 1.69) | 1.00 | 1.12 (0.93 1.36) | ||
| Stomach | Cases | 348 | 14 | 177 | 141 | 16 | |
| HR (95% CI)* | 0.77 (0.45 1.33) | 1.00 | 1.58 (0.95 2.63) | ||||
| HR (95% CI)† | 1.03 (0.98 1.08) | 0.19 | 0.75 (0.43 1.32) | 1.00 | 1.12 (0.89 1.42) | 1.07 (0.61 1.85) | |
| HR (95% CI) | 1.03 (0.98 1.08) | 0.19 | 0.75 (0.43 1.32) | 1.00 | 1.12 (0.89 1.42) | 1.07 (0.61 1.85) | |
| Oesophagus and stomach | Cases | 870 | 42 | 444 | 356 | 28 | |
| HR (95% CI)* | 0.93 (0.68 1.28) | 1.00 | 1.09 (0.74 1.59) | ||||
| HR (95% CI)† | 1.02 (0.98 1.05) | 0.31 | 0.99 (0.72 1.36) | 1.00 | 1.14 (0.98 1.32) | 0.76 (0.50 1.14) | |
| HR (95% CI)f | 1.02 (0.98 1.05) | 0.34 | 0.99 (0.72 1.37) | 1.00 | 1.13 (0.98 1.31) | 0.76 (0.50 1.14) | |
| Hepatobiliary tract | Cases | 446 | 22 | 249 | 156 | 19 | |
| HR (95% CI)* | 0.84 (0.54 1.29) | 1.00 | 1.11 (0.90 1.35) | 1.45 (0.91 2.31) | |||
| HR (95% CI)† | 1.01 (0.96 1.05) | 0.73 | 0.82 (0.52 1.30) | 1.00 | 0.95 (0.77 1.18) | 1.05 (0.65 1.72) | |
| HR (95% CI) | 1.01 (0.96 1.05) | 0.73 | 0.82 (0.52 1.30) | 1.00 | 0.95 (0.77 1.18) | 1.05 (0.65 1.72) | |
| Pancreatic | Cases | 604 | 30 | 333 | 220 | 21 | |
| HR (95% CI)* | 0.85 (0.58 1.23) | 1.00 | 1.22 (0.78 1.89) | ||||
| HR (95% CI)† | 1.02 (0.98 1.06) | 0.37 | 0.86 (0.58 1.26) | 1.00 | 1.10 (0.92 1.31) | 1.01 (0.64 1.60) | |
| HR (95% CI)d | 1.02 (0.98 1.06) | 0.45 | 0.86 (0.58 1.26) | 1.00 | 1.08 (0.91 1.30) | 0.99 (0.63 1.57) | |
| Kidney | Cases | 771 | 43 | 417 | 279 | 32 | |
| HR (95% CI)* | 0.98 (0.71 1.34) | 1.00 | 1.19 (1.02 1.38) | 1.38 (0.96 1.98) | |||
| HR (95% CI)† | 1.01 (0.97 1.04) | 0.67** | 1.03 (0.74 1.44) | 1.00 | 1.07 (0.91 1.25) | 1.14 (0.79 1.66) | |
| HR (95% CI) | 1.01 (0.97 1.04) | 0.67** | 1.03 (0.74 1.44) | 1.00 | 1.07 (0.91 1.25) | 1.14 (0.79 1.66) | |
| Bladder | Cases | 662 | 24 | 351 | 259 | 28 | |
| HR (95% CI)* | 0.69 (0.46 1.04) | 1.00 | 1.36 (0.93 2.00) | ||||
| HR (95% CI)† | 1.01 (0.98 1.05) | 0.50** | 0.76 (0.50 1.16) | 1.00 | 1.10 (0.93 1.30) | 0.99 (0.65 1.53) | |
| HR (95% CI) | 1.01 (0.98 1.05) | 0.50** | 0.76 (0.50 1.16) | 1.00 | 1.10 (0.93 1.30) | 0.99 (0.65 1.53) | |
| Colorectal | Cases | 3290 | 180 | 1896 | 1096 | 118 | |
| HR (95% CI)* | 0.03** | 0.88 (0.76 1.03) | 1.00 | 1.04 (0.97 1.12) | 1.16 (0.97 1.40) | ||
| HR (95% CI)† | 1.01 (0.99 1.03) | 0.41** | 0.92 (0.79 1.08) | 1.00 | 1.003 (0.93 1.08) | 1.11 (0.91 1.35) | |
| HR (95% CI)e, g, f (males) | 1.01 (0.99 1.02) | 0.58** | 0.89 (0.76 1.04) | 1.00 | 0.99 (0.91 1.07) | 1.08 (0.88 1.32) | |
| Colon | Cases | 2110 | 111 | 1202 | 721 | 76 | |
| HR (95% CI)* | 0.86 (0.70 1.04) | 1.00 | 1.08 (0.99 1.19) | 1.21 (0.96 1.53) | |||
| HR (95% CI)† | 1.02 (0.998 1.04) | 0.08** | 0.91 (0.75 1.11) | 1.00 | 1.04 (0.95 1.15) | 1.16 (0.91 1.48) | |
| HR (95% CI)e, g, f (males) | 1.02 (0.99 1.04) | 0.15** | 0.90 (0.73 1.10) | 1.00 | 1.04 (0.94 1.15) | 1.12 (0.88 1.44) | |
| Rectum | Cases | 1107 | 64 | 645 | 358 | 40 | |
| HR (95% CI)* | 0.998 (0.97 1.03) | 0.89** | 0.94 (0.73 1.21) | 1.00 | 0.99 (0.87 1.13) | 1.10 (0.80 1.51) | |
| HR (95% CI)† | 0.99 (0.96 1.02) | 0.38 | 0.95 (0.73 1.25) | 1.00 | 0.95 (0.83 1.09) | 1.04 (0.74 1.46) | |
| HR (95% CI)e, g | 0.98 (0.95 1.02) | 0.31 | 0.91 (0.69 1.20) | 1.00 | 0.92 (0.80 1.06) | 1.01 (0.72 1.43) | |
| Brain tumours | Cases | 458 | 28 | 269 | 145 | 16 | |
| HR (95% CI)* | 1.01 (0.97 1.06) | 0.50 | 0.96 (0.65 1.42) | 1.00 | 0.99 (0.81 1.22) | 1.07 (0.65 1.77) | |
| HR (95% CI)† | 1.02 (0.98 1.07) | 0.31 | 0.98 (0.66 1.46) | 1.00 | 1.001 (0.81 1.24) | 1.13 (0.67 1.91) | |
| HR (95% CI)f | 1.03 (0.98 1.07) | 0.28 | 0.97 (0.65 1.45) | 1.00 | 1.01 (0.81 1.25) | 1.13 (0.67 1.92) | |
| Thyroid | Cases | 236 | 15 | 154 | 62 | 5 | |
| HR (95% CI)* | 0.99 (0.93 1.06) | 0.86 | 0.78 (0.46 1.32) | 1.00 | 0.87 (0.65 1.18) | 0.71 (0.29 1.72) | |
| HR (95% CI)† | 0.999 (0.93 1.07) | 0.97 | 0.76 (0.44 1.32) | 1.00 | 0.88 (0.64 1.20) | 0.70 (0.28 1.72) | |
| HR (95% CI) | 0.999 (0.93 1.07) | 0.97 | 0.76 (0.44 1.32) | 1.00 | 0.88 (0.64 1.20) | 0.70 (0.28 1.72) | |
| Haematological malignancies | Cases | 2427 | 142 | 1396 | 806 | 83 | |
| HR (95% CI)* | 1.02 (0.998 1.04) | 0.09 | 0.95 (0.80 1.12) | 1.00 | 1.04 (0.96 1.14) | 1.12 (0.90 1.40) | |
| HR (95% CI)† | 1.01 (0.99 1.03) | 0.43 | 0.96 (0.80 1.15) | 1.00 | 1.02 (0.93 1.12) | 1.07 (0.85 1.34) | |
| HR (95% CI) | 1.01 (0.99 1.03) | 0.43 | 0.96 (0.80 1.15) | 1.00 | 1.02 (0.93 1.12) | 1.07 (0.85 1.34) | |
| Non-Hodgkin’s lymphoma | Cases | 1174 | 68 | 675 | 392 | 39 | |
| HR (95% CI)* | 1.02 (0.99 1.04) | 0.28 | 0.93 (0.72 1.19) | 1.00 | 1.06 (0.93 1.20) | 1.10 (0.80 1.52) | |
| HR (95% CI)† | 1.01 (0.98 1.04) | 0.43 | 0.93 (0.72 1.20) | 1.00 | 1.08 (0.95 1.23) | 1.06 (0.75 1.48) | |
| HR (95% CI) | 1.01 (0.98 1.04) | 0.43 | 0.93 (0.72 1.20) | 1.00 | 1.08 (0.95 1.23) | 1.06 (0.75 1.48) |
*Models adjusted for age and sex (total observations = 464,424)
†Models adjusted for age, sex, ethnicity (white/other), deprivation index (quintiles), education (University degree, A-levels/HNC/HND/NVQ, GCSE/O-level/CSE, OTHER, None), fruit and vegetable intake (< 5 portions/day, ≥5 portions/day), BMI (kg/m2), height (m), smoking status (never, former light smoker [< 20 pack-years], former heavy smoker [≥20 pack-years], current light smoker [< 20 pack-years], current heavy smoker [≥20 pack-years]) and alcohol intake (never, former, current [
aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
gResults for males and females combined using meta-analysis as covariates are different
hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
**Schoenfeld test indicated potential violation of the proportional hazards assumption (p < 0.05)
Baseline characteristics by self-report daily TV viewing time. Values are numbers and percentages unless otherwise stated
| Total TV viewing time | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | ≤1 h per day | 1- ≤ 3 h per day | 3- ≤ 5 h per day | > 5 h/day | ||||||
| No./mean | %/SD | No./mean | %/SD | No./mean | %/SD | No./mean | %/SD | No./mean | %/SD | |
| 470,578 | 100.0% | 97,419 | 20.7% | 236,988 | 50.4% | 110,334 | 23.5% | 25,837 | 5.5% | |
| 3.9 | 2.1 | 2.0 | 1.5 | 3.5 | 1.4 | 5.3 | 1.4 | 7.9 | 2.4 | |
| Time spent watching TV (hours/day; mean/SD) | 2.8 | 1.7 | 0.7 | 0.4 | 2.5 | 0.5 | 4.3 | 0.5 | 6.9 | 1.8 |
| Time spent using computers (hours/day; mean/SD) | 1.1 | 1.4 | 1.2 | 1.5 | 1.1 | 1.3 | 1.0 | 1.3 | 1.1 | 1.7 |
| Hours/day of walking | 0.75 | 0.78 | 0.71 | 0.74 | 0.76 | 0.79 | 0.77 | 0.79 | 0.67 | 0.74 |
| Hours/day of moderate-intensity physical activity | 0.56 | 0.72 | 0.54 | 0.70 | 0.57 | 0.73 | 0.58 | 0.74 | 0.46 | 0.67 |
| Hours/day of vigorous-intensity physical activity | 0.20 | 0.35 | 0.22 | 0.34 | 0.20 | 0.35 | 0.18 | 0.35 | 0.14 | 0.33 |
| 56.3 | 8.1 | 54.2 | 8.0 | 55.9 | 8.1 | 58.5 | 7.6 | 59.0 | 7.6 | |
| 1.7 | 0.1 | 1.7 | 0.1 | 1.7 | 0.1 | 1.7 | 0.1 | 1.7 | 0.1 | |
| Female | 253,188 | 53.8% | 53,500 | 54.9% | 127,135 | 53.7% | 59,553 | 54.0% | 13,000 | 50.3% |
| Male | 217,390 | 46.2% | 43,919 | 45.1% | 109,853 | 46.4% | 50,781 | 46.0% | 12,837 | 49.7% |
| White | 443,484 | 94.6% | 90,405 | 93.3% | 224,142 | 94.9% | 104,922 | 95.4% | 24,015 | 93.3% |
| Black | 7505 | 1.6% | 1549 | 1.6% | 3358 | 1.4% | 1846 | 1.7% | 752 | 2.9% |
| South Asian | 9395 | 2.0% | 2582 | 2.7% | 4721 | 2.0% | 1639 | 1.5% | 453 | 1.8% |
| Chinese | 1501 | 0.3% | 465 | 0.5% | 717 | 0.3% | 266 | 0.2% | 53 | 0.2% |
| Mixed background or others | 7069 | 1.5% | 1949 | 2.0% | 3299 | 1.4% | 1354 | 1.2% | 467 | 1.8% |
| 1 (Least deprived) | 94,590 | 20.1% | 19,860 | 20.4% | 51,164 | 21.6% | 20,497 | 18.6% | 3069 | 11.9% |
| 2 | 93,950 | 20.0% | 18,854 | 19.4% | 49,804 | 21.0% | 21,691 | 19.7% | 3601 | 14.0% |
| 3 | 94,166 | 20.0% | 18,857 | 19.4% | 48,706 | 20.6% | 22,379 | 20.3% | 4224 | 16.4% |
| 4 | 94,118 | 20.0% | 20,209 | 20.8% | 46,505 | 19.7% | 22,081 | 20.0% | 5323 | 20.6% |
| 5 (Most deprived) | 93,165 | 19.8% | 19,530 | 20.1% | 40,495 | 17.1% | 23,561 | 21.4% | 9579 | 37.1% |
| University degree | 153,223 | 33.1% | 52,250 | 54.3% | 79,041 | 33.9% | 19,257 | 17.8% | 2675 | 10.6% |
| A-levels/HNC/HND/NVQ | 83,315 | 18.0% | 15,934 | 16.6% | 44,649 | 19.1% | 18,921 | 17.5% | 3811 | 15.1% |
| GCSE/O-level/CSE | 124,765 | 26.9% | 17,518 | 18.2% | 66,180 | 28.3% | 34,257 | 31.6% | 6810 | 27.0% |
| Other | 24,018 | 5.2% | 4230 | 4.4% | 12,530 | 5.4% | 6091 | 5.6% | 1167 | 4.6% |
| None | 78,028 | 16.8% | 6346 | 6.6% | 31,125 | 13.3% | 29,800 | 27.5% | 10,757 | 42.7% |
| Never | 257,696 | 55.0% | 58,981 | 60.7% | 132,976 | 56.3% | 54,858 | 49.9% | 10,881 | 42.4% |
| Former light smoker | 119,085 | 25.4% | 24,556 | 25.3% | 61,147 | 25.9% | 27,891 | 25.4% | 5491 | 21.4% |
| Former heavy smoker | 42,251 | 9.0% | 5350 | 5.5% | 19,256 | 8.2% | 13,521 | 12.3% | 4124 | 16.1% |
| Current light smoker | 27,794 | 5.9% | 5535 | 5.7% | 13,706 | 5.8% | 6646 | 6.1% | 1907 | 7.4% |
| Current heavy smoker | 22,082 | 4.7% | 2735 | 2.8% | 9094 | 3.9% | 6972 | 6.3% | 3281 | 12.8% |
| Never | 20,749 | 4.4% | 4873 | 5.0% | 9428 | 4.0% | 4868 | 4.4% | 1580 | 6.1% |
| Former drinker | 16,659 | 3.5% | 3330 | 3.4% | 7128 | 3.0% | 4342 | 3.9% | 1859 | 7.2% |
| Current drinker: <once/week | 106,020 | 22.6% | 19,466 | 20.0% | 50,958 | 21.5% | 27,939 | 25.3% | 7657 | 29.7% |
| Current drinker: ≥once/week | 326,759 | 69.5% | 69,676 | 71.6% | 169,324 | 71.5% | 73,089 | 66.3% | 14,670 | 56.9% |
| Fruits and vegetables (portion/day) | 4.7 | 3.1 | 5.1 | 3.2 | 4.7 | 3.0 | 4.5 | 3.0 | 4.2 | 3.3 |
| Red meat (portion/week) | 2.1 | 1.5 | 2.0 | 1.4 | 2.1 | 1.4 | 2.2 | 1.5 | 2.4 | 1.7 |
| Processed meat (portion/week) | 1.5 | 1.4 | 1.3 | 1.4 | 1.5 | 1.4 | 1.6 | 1.4 | 1.9 | 1.6 |
| 27.4 | 4.8 | 26.0 | 4.3 | 27.3 | 4.6 | 28.5 | 4.9 | 29.7 | 5.8 | |
| < 18.5 | 2418 | 0.5% | 825 | 0.9% | 1113 | 0.5% | 352 | 0.3% | 128 | 0.5% |
| 18.5- < 25 | 152,533 | 32.6% | 44,075 | 45.5% | 77,507 | 32.9% | 26,157 | 23.8% | 4794 | 18.8% |
| 25- < 30 | 199,212 | 42.6% | 37,528 | 38.7% | 103,141 | 43.7% | 48,586 | 44.3% | 9957 | 39.1% |
| 30+ | 113,922 | 24.3% | 14,489 | 15.0% | 54,197 | 23.0% | 34,626 | 31.6% | 10,610 | 41.6% |
| 31.3 | 8.5 | 28.9 | 8.3 | 31.1 | 8.4 | 33.2 | 8.4 | 34.3 | 8.8 | |
| Waist:hip ratio (mean/SD) | 0.9 | 0.1 | 0.9 | 0.1 | 0.9 | 0.1 | 0.9 | 0.1 | 0.9 | 0.1 |
| Below IDF guideline | 202,545 | 43.2% | 54,750 | 56.4% | 104,482 | 44.2% | 36,717 | 33.4% | 6596 | 25.7% |
| Above IDF guideline | 266,443 | 56.8% | 42,333 | 43.6% | 131,829 | 55.8% | 73,249 | 66.6% | 19,032 | 74.3% |
| Diabetesc | 24,347 | 5.2% | 3085 | 3.2% | 10,404 | 4.4% | 7687 | 7.0% | 3171 | 12.4% |
| Gastro-oesophageal refluxd | 22,495 | 4.8% | 3233 | 3.3% | 10,672 | 4.5% | 6648 | 6.0% | 1942 | 7.5% |
| Prostate cancer | 37,225 | 8.0% | 8431 | 8.8% | 18,607 | 8.0% | 8332 | 7.7% | 1855 | 7.3% |
| Breast cancer | 49,524 | 10.7% | 10,520 | 10.9% | 24,986 | 10.7% | 11,360 | 10.5% | 2658 | 10.5% |
| Lung cancer | 59,042 | 12.7% | 9596 | 10.0% | 29,218 | 12.5% | 16,107 | 14.9% | 4121 | 16.3% |
| Bowel cancer | 52,109 | 11.2% | 10,181 | 10.6% | 25,851 | 11.1% | 12,943 | 11.9% | 3134 | 12.4% |
| Never/rarely/sometimes | 203,968 | 43.7% | 43,450 | 44.9% | 99,121 | 42.1% | 48,286 | 44.1% | 13,111 | 51.4% |
| Most of the time/always | 260,241 | 55.7% | 52,699 | 54.5% | 135,033 | 57.4% | 60,493 | 55.3% | 12,016 | 47.1% |
| Do not go out in sunshine | 2770 | 0.6% | 538 | 0.6% | 1136 | 0.5% | 717 | 0.7% | 379 | 1.5% |
| Regularly uses aspirinf | 64,822 | 14.0% | 9711 | 10.1% | 29,908 | 12.9% | 19,246 | 17.8% | 5957 | 23.7% |
| Ever used HRT | 95,369 | 37.8% | 14,791 | 27.8% | 46,587 | 36.8% | 27,639 | 46.6% | 6352 | 49.1% |
| Ever taken oral contraceptive pill | 205,528 | 81.4% | 44,285 | 83.0% | 104,772 | 82.7% | 46,695 | 78.7% | 9776 | 75.6% |
| 1.8 | 1.2 | 1.8 | 1.2 | 1.8 | 1.2 | 1.9 | 1.2 | 2.0 | 1.3 | |
| 13.0 | 1.6 | 13.0 | 1.6 | 13.0 | 1.6 | 13.0 | 1.7 | 13.0 | 1.7 | |
| 49.8 | 5.1 | 50.0 | 4.7 | 49.9 | 5.0 | 49.6 | 5.4 | 49.0 | 5.8 | |
| Had menopause | 151,101 | 59.8% | 27,736 | 51.9% | 74,075 | 58.4% | 40,399 | 68.0% | 8891 | 68.6% |
| Not had menopause | 62,570 | 24.8% | 18,659 | 34.9% | 33,174 | 26.1% | 9075 | 15.3% | 1662 | 12.8% |
| Unsure | 39,065 | 15.5% | 7002 | 13.1% | 19,684 | 15.5% | 9969 | 16.8% | 2410 | 18.6% |
| Had hysterectomy | 17,530 | 7.8% | 2458 | 5.0% | 8193 | 7.2% | 5483 | 10.6% | 1396 | 12.7% |
| Not had hysterectomy/unsure | 207,953 | 92.2% | 46,846 | 95.0% | 105,238 | 92.8% | 46,232 | 89.4% | 9637 | 87.4% |
CSE: Certificate of Secondary Education; GCSE: General Certificate of Secondary Education; HNC: Higher National Certificate; HND: Higher National Diploma; HRT: hormone-replacement therapy; IDF: International Diabetes Federation; MVPA: moderate-vigorous intensity physical activity; NVQ: National Vocational Qualifications; UV: ultraviolet
aDefined in terms of pack-years: light (< 20 pack-years), heavy (≥20 pack-years)
bBased on IDF criteria (waist circumference > 94 cm in men; > 80 cm in women)
cDiagnosed by doctor
dSelf-reported
eBased on self-reported illnesses of father, mother and siblings
fRegular use defined as most days of the week for the last 4 weeks
gFemale participants only
Fig. 1Summary hazard ratio estimates by cancer site
Results of Cox proportional hazards analyses investigating the association between self-report daily TV viewing time and cancer incidence (excluding cancers diagnosed within the first 2 years following baseline)
| 1 h increase in TV viewing time | ≤1 h | 1- ≤ 3 h (reference) | 3- ≤ 5 h | > 5 h | |||
|---|---|---|---|---|---|---|---|
| Skin, melanoma | Cases | 1192 | 222 | 613 | 299 | 58 | |
| HR (95% CI)a | 1.02(0.98,1.06) | 0.39** | 0.93(0.80,1.09) | 1.00 | 1.04(0.90,1.20) | 1.004(0.76,1.33) | |
| Oropharyngeal | Cases | 410 | 69 | 197 | 105 | 39 | |
| HR (95% CI) | 1.04(0.99,1.10) | 0.12 | 0.90(0.68,1.19) | 1.00 | 1.02(0.80,1.30) | 1.27(0.89,1.84) | |
| Lung | Cases | 1461 | 165 | 638 | 467 | 191 | |
| HR (95% CI)h | 1.02(0.99,1.05) | 0.21** | 0.87(0.73,1.03) | 1.00 | 0.97(0.86,1.10) | 1.10(0.93,1.30) | |
| Breast (female only) | Cases | 3288 | 657 | 1724 | 756 | 151 | |
| HR (95% CI)b, h | 1.004(0.98,1.03) | 0.76** | 1.00 | 0.96(0.87,1.04) | 0.94(0.79,1.11) | ||
| Uterus | Cases | 567 | 102 | 270 | 165 | 30 | |
| HR (95% CI)c | 0.98(0.93,1.04) | 0.56** | 1.05(0.83,1.33) | 1.00 | 1.06(0.87,1.29) | 0.75(0.50,1.10) | |
| Ovary | Cases | 404 | 69 | 204 | 109 | 22 | |
| HR (95% CI) | 1.02(0.95,1.09) | 0.60 | 0.88(0.67,1.16) | 1.00 | 1.01(0.80,1.29) | 0.93(0.59,1.46) | |
| Prostate | Cases | 4235 | 804 | 2127 | 1069 | 235 | |
| HR (95% CI)h | 0.99(0.97,1.01) | 0.34** | 1.02(0.94,1.10) | 1.00 | 0.98(0.91,1.06) | 0.94(0.82,1.08) | |
| Oesophagus | Cases | 392 | 46 | 182 | 125 | 39 | |
| HR (95% CI)f | 1.04(0.98,1.10) | 0.20** | 0.79(0.57,1.10) | 1.00 | 1.08(0.86,1.37) | 1.11(0.77,1.60) | |
| Stomach | Cases | 250 | 24 | 125 | 78 | 23 | |
| HR (95% CI) | 1.06(0.99,1.14) | 0.09 | 1.00 | 0.996(0.74,1.33) | 0.96(0.60,1.53) | ||
| Oesophagus and stomach | Cases | 638 | 70 | 303 | 203 | 62 | |
| HR (95% CI) | 1.00 | 1.07(0.89,1.28) | 1.07(0.80,1.42) | ||||
| Hepatobiliary tract | Cases | 348 | 51 | 156 | 100 | 41 | |
| HR (95% CI) | 1.03(0.97,1.10) | 0.29 | 0.9999(0.72,1.38) | 1.00 | 1.001(0.77,1.29) | 1.36(0.94,1.95) | |
| Pancreatic | Cases | 463 | 75 | 215 | 140 | 33 | |
| HR (95% CI)d | 1.01(0.95,1.06) | 0.85 | 1.02(0.78,1.33) | 1.00 | 1.09(0.88,1.36) | 0.91(0.62,1.34) | |
| Kidney | Cases | 583 | 90 | 280 | 161 | 52 | |
| HR (95% CI) | 0.99(0.94,1.04) | 0.75 | 1.02(0.80,1.30) | 1.00 | 0.95(0.77,1.15) | 1.11(0.81,1.51) | |
| Bladder | Cases | 461 | 57 | 208 | 155 | 41 | |
| HR (95% CI) | 1.03(0.98,1.09) | 0.25** | 0.88(0.65,1.19) | 1.00 | 1.19(0.96,1.47) | 1.10(0.77,1.55) | |
| Colorectal | Cases | 2281 | 383 | 1118 | 621 | 159 | |
| HR (95% CI)e, g, f (males) | 1.03(0.998,1.05) | 0.07** | 0.95(0.85,1.07) | 1.00 | 1.03(0.93,1.14) | 1.10(0.93,1.31) | |
| Colon | Cases | 1478 | 246 | 712 | 407 | 113 | |
| HR (95% CI)e, g, f (males) | 0.97(0.84,1.13) | 1.00 | 1.05(0.92,1.19) | 1.22(0.99,1.50) | |||
| Rectum | Cases | 754 | 134 | 373 | 201 | 46 | |
| HR (95% CI)e, g | 1.000(0.96,1.05) | 0.995 | 0.98(0.80,1.20) | 1.00 | 1.03(0.87,1.23) | 0.99(0.72,1.36) | |
| Brain tumours | Cases | 333 | 58 | 178 | 80 | 17 | |
| HR (95% CI) | 1.03(0.96,1.11) | 0.38 | 0.85(0.62,1.15) | 1.00 | 0.89(0.68,1.17) | 0.81(0.48,1.35) | |
| Thyroid | Cases | 161 | 32 | 85 | 35 | 9 | |
| HR (95% CI) | 0.99(0.89,1.09) | 0.78 | 0.91(0.60,1.38) | 1.00 | 0.88(0.59,1.32) | 0.998(0.49,2.03) | |
| Haematological malignancies | Cases | 1786 | 315 | 888 | 470 | 113 | |
| HR (95% CI) | 1.003(0.97,1.03) | 0.86** | 0.96(0.84,1.10) | 1.00 | 0.98(0.87,1.10) | 0.95(0.78,1.17) | |
| Non-Hodgkin’s lymphoma | Cases | 886 | 138 | 431 | 254 | 43 | |
| HR (95% CI) | 1.02(0.98,1.07) | 0.26 | 0.84(0.69,1.02) | 1.00 | 1.12(0.95,1.31) | 0.78(0.57,1.08) |
aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
gResults for males and females combined using meta-analysis as covariates are different
hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
**Schoenfeld test indicated potential violation of the proportional hazards assumption (p < 0.05)
Results of isotemporal substitution models showing the impact on cancer incidence of replacing a 1-h of total daily TV viewing time with the same amount of daily moderate activity, daily vigorous activity or daily walking time, holding the other activities constant
| 1-h increase in daily moderate activity | 1-h increase in daily vigorous activity | 1-h increase in daily walking time | |
|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |
[cases = 1256]a | 0.98 (0.89, 1.09) | 0.97 (0.81, 1.17) | 1.03 (0.94, 1.12) |
[cases = 411] | 0.91 (0.77, 1.08) | 0.86 (0.63, 1.18) | |
[cases = 1355]h | 1.0003 (0.92, 1.09) | 0.84 (0.71, 1.004) | |
[cases = 3454]b, h | 1.02 (0.89, 1.16) | 0.99 (0.94, 1.05) | |
[cases = 570]c | 1.001 (0.86, 1.17) | 1.05 (0.76, 1.46) | 0.99 (0.86, 1.13) |
[cases = 405] | 1.09 (0.93, 1.28) | 1.12 (0.81, 1.55) | 0.97 (0.83, 1.13) |
[cases = 4629]h | 1.01 (0.96, 1.06) | 1.05 (0.97, 1.15) | 0.9997 (0.95, 1.05) |
[cases = 386]f | 1.09 (0.93, 1.28) | 1.06 (0.80, 1.42) | 0.91 (0.77, 1.06) |
[cases = 264] | 1.06 (0.87, 1.29) | 0.77 (0.52, 1.15) | 0.91 (0.76, 1.10) |
[cases = 644] | 1.08 (0.95, 1.22) | 0.94 (0.74, 1.18) | 0.90 (0.80, 1.02) |
[cases = 331] | 0.84 (0.69, 1.02) | 1.01 (0.71, 1.43) | 1.03 (0.87, 1.21) |
[cases = 467]d | 1.07 (0.92, 1.24) | 0.92 (0.69, 1.23) | 0.95 (0.82, 1.09) |
[cases = 559] | 1.01 (0.88, 1.17) | 1.12 (0.87, 1.44) | 0.95 (0.83, 1.09) |
[cases = 502] | 0.98 (0.85, 1.13) | 0.83 (0.62, 1.09) | 1.03 (0.90, 1.17) |
[cases = 2405]e, g, f (males) | 0.997 (0.87, 1.14) | 1.01 (0.95, 1.08) | |
[cases = 1530]e, g, f (males) | 0.96 (0.81, 1.14) | 1.001 (0.92, 1.09) | |
[cases = 821]e, g | 0.99 (0.88, 1.12) | 1.06 (0.86, 1.30) | 1.01 (0.90, 1.12) |
[cases = 345] | 0.85 (0.70, 1.03) | 0.85 (0.59, 1.23) | 1.04 (0.88, 1.23) |
[cases = 181] | 0.94 (0.72, 1.23) | 0.80 (0.46, 1.40) | 1.07 (0.85, 1.35) |
[cases = 1794] | 0.98 (0.90, 1.06) | 1.07 (0.93, 1.24) | 0.99 (0.92, 1.07) |
[cases = 864] | 0.99 (0.88, 1.11) | 1.07 (0.87, 1.32) | 0.95 (0.85, 1.06) |
All models were adjusted for age, sex, ethnicity (white/other), deprivation index (quintiles), education (University degree, A-levels/HNC/HND/NVQ, GCSE/O-level/CSE, OTHER, None), fruit and vegetable intake (< 5 portions/day, ≥5 portions/day), BMI (kg/m2), height (m), smoking status (never, former light smoker [< 20 pack-years], former heavy smoker [≥20 pack-years], current light smoker [< 20 pack-years], current heavy smoker [≥20 pack-years]) and alcohol intake (never, former, current [
aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
gResults for males and females combined using meta-analysis as covariates are different
hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
Results of Cox proportional hazards analyses investigating the association between self-report daily computer use time and cancer incidence
| 1 h increase in computer use time | None | ≤1 h (reference) | 1- ≤ 3 h | > 3 h | |||
|---|---|---|---|---|---|---|---|
| Person-years | 3,498,487 | 969,721 | 1,744,785 | 582,168 | 201,813 | ||
| Skin, melanoma | Cases | 1621 | 404 | 852 | 276 | 89 | |
| HR (95% CI)* | 1.01 (0.98 1.05) | 0.43** | 1.00 | 0.90 (0.79 1.04) | 0.92 (0.74 1.14) | ||
| HR (95% CI)† | 1.01 (0.97 1.05) | 0.72 | 0.90 (0.79 1.02) | 1.00 | 0.97 (0.85 1.12) | 0.99 (0.79 1.24) | |
| HR (95% CI)a | 1.01 (0.97 1.05) | 0.73 | 0.91 (0.80 1.03) | 1.00 | 0.98 (0.85 1.12) | 0.996 (0.79 1.25) | |
| Oropharyngeal | Cases | 561 | 209 | 239 | 88 | 25 | |
| HR (95% CI)* | 1.00 | 0.97 (0.76 1.23) | 0.81 (0.54 1.23) | ||||
| HR (95% CI)† | 1.00 | 0.91 (0.71 1.17) | 0.77 (0.51 1.17) | ||||
| HR (95% CI) | 1.00 | 0.91 (0.71 1.17) | 0.77 (0.51 1.17) | ||||
| Lung | Cases | 2040 | 894 | 700 | 316 | 130 | |
| HR (95% CI)* | 0.97 (0.93 1.003) | 0.08** | 1.00 | ||||
| HR (95% CI)† | 1.02 (0.99 1.06) | 0.16** | 1.10 (0.99 1.23) | 1.00 | 1.01 (0.88 1.16) | ||
| HR (95% CI)h | 1.02 (0.99 1.06) | 1.11 (0.99 1.24) | 1.00 | 0.996 (0.87 1.15) | |||
| Breast (female only) | Cases | 5650 | 1728 | 2931 | 762 | 229 | |
| HR (95% CI)* | 1.01 (0.99 1.03) | 0.27** | 1.00 | 1.02 (0.94 1.10) | 0.997 (0.87 1.14) | ||
| HR (95% CI)† | 1.003 (0.98 1.03) | 0.83** | 0.97 (0.91 1.04) | 1.00 | 0.999 (0.92 1.08) | 1.001 (0.87 1.15) | |
| HR (95% CI)b, f, h | 1.01 (0.98 1.03) | 0.57** | 0.96 (0.90 1.04) | 1.00 | 0.998 (0.91 1.09) | 1.03 (0.89 1.20) | |
| Uterus | Cases | 863 | 315 | 389 | 127 | 32 | |
| HR (95% CI)* | 1.01 (0.95 1.07) | 0.74 | 1.00 | 1.12 (0.78 1.60) | |||
| HR (95% CI)† | 0.96 (0.90 1.02) | 0.20 | 1.18 (0.999 1.39) | 1.00 | 1.04 (0.84 1.28) | 0.91 (0.63 1.33) | |
| HR (95% CI)c | 0.98 (0.92 1.04) | 0.47 | 1.16 (0.98 1.37) | 1.00 | 1.08 (0.87 1.35) | 0.95 (0.64 1.40) | |
| Ovary | Cases | 567 | 211 | 266 | 63 | 27 | |
| HR (95% CI)* | 0.98 (0.91 1.05) | 0.51 | 1.16 (0.96 1.39) | 1.00 | 0.91 (0.69 1.19) | 1.36 (0.91 2.02) | |
| HR (95% CI)† | 0.96 (0.89 1.04) | 0.36 | 1.00 | 0.91 (0.69 1.21) | 1.36 (0.91 2.04) | ||
| HR (95% CI) | 0.96 (0.89 1.04) | 0.36 | 1.00 | 0.91 (0.69 1.21) | 1.36 (0.91 2.04) | ||
| Prostate | Cases | 5933 | 1543 | 2699 | 1298 | 393 | |
| HR (95% CI)* | 1.005 (0.99 1.02) | 0.61** | 1.00 | 0.97 (0.91 1.03) | 0.97 (0.87 1.07) | ||
| HR (95% CI)† | 0.998 (0.98 1.02) | 0.85** | 0.98 (0.92 1.06) | 1.00 | 0.99 (0.93 1.06) | 0.9998 (0.90 1.12) | |
| HR (95% CI)h | 0.997 (0.98 1.02) | 0.73** | 0.99 (0.92 1.06) | 1.00 | 0.99 (0.93 1.06) | 0.99 (0.89 1.11) | |
| Oesophagus | Cases | 530 | 174 | 221 | 108 | 27 | |
| HR (95% CI)* | 0.97 (0.90 1.03) | 0.32 | 1.20 (0.98 1.47) | 1.00 | 1.13 (0.90 1.42) | 0.94 (0.63 1.41) | |
| HR (95% CI)† | 0.97 (0.90 1.04) | 0.37 | 0.99 (0.79 1.23) | 1.00 | 1.02 (0.81 1.30) | 0.78 (0.51 1.19) | |
| HR (95% CI)f | 0.97 (0.90 1.04) | 0.35 | 0.99 (0.79 1.23) | 1.00 | 1.02 (0.80 1.30) | 0.77 (0.51 1.18) | |
| Stomach | Cases | 349 | 133 | 133 | 61 | 22 | |
| HR (95% CI)* | 0.98 (0.90 1.06) | 0.60 | 1.00 | 1.09 (0.80 1.47) | 1.30 (0.83 2.05) | ||
| HR (95% CI)† | 0.98 (0.91 1.07) | 0.71 | 1.16 (0.88 1.51) | 1.00 | 0.98 (0.72 1.35) | 1.04 (0.64 1.69) | |
| HR (95% CI) | 0.98 (0.91 1.07) | 0.71 | 1.16 (0.88 1.51) | 1.00 | 0.98 (0.72 1.35) | 1.04 (0.64 1.69) | |
| Oesophagus and stomach | Cases | 873 | 305 | 352 | 168 | 48 | |
| HR (95% CI)* | 0.97 (0.92 1.02) | 0.25 | 1.00 | 1.11 (0.93 1.34) | 1.06 (0.79 1.44) | ||
| HR (95% CI)† | 0.97 (0.92 1.03) | 0.33 | 1.05 (0.89 1.25) | 1.00 | 1.01 (0.83 1.22) | 0.86 (0.62 1.19) | |
| HR (95% CI)f | 0.97 (0.92 1.03) | 0.32 | 1.05 (0.89 1.25) | 1.00 | 1.01 (0.83 1.22) | 0.86 (0.62 1.19) | |
| Hepatobiliary tract | Cases | 451 | 170 | 168 | 91 | 22 | |
| HR (95% CI)* | 0.97 (0.90 1.04) | 0.42 | 1.00 | 1.14 (0.73 1.77) | |||
| HR (95% CI)† | 0.99 (0.92 1.06) | 0.74 | 1.21 (0.95 1.53) | 1.00 | 1.30 (0.997 1.69) | 1.02 (0.65 1.61) | |
| HR (95% CI) | 0.99 (0.92 1.06) | 0.74 | 1.21 (0.95 1.53) | 1.00 | 1.30 (0.997 1.69) | 1.02 (0.65 1.61) | |
| Pancreatic | Cases | 606 | 189 | 276 | 114 | 27 | |
| HR (95% CI)* | 0.98 (0.92 1.05) | 0.62 | 1.01 (0.83 1.21) | 1.00 | 1.07 (0.86 1.34) | 0.87 (0.59 1.29) | |
| HR (95% CI)† | 0.98 (0.92 1.05) | 0.62 | 0.90 (0.73 1.11) | 1.00 | 1.05 (0.84 1.31) | 0.76 (0.50 1.15) | |
| HR (95% CI)d | 0.98 (0.92 1.05) | 0.61 | 0.90 (0.73 1.10) | 1.00 | 1.05 (0.84 1.31) | 0.76 (0.50 1.14) | |
| Kidney | Cases | 783 | 251 | 333 | 149 | 50 | |
| HR (95% CI)* | 1.01 (0.96 1.07) | 0.60 | 1.17 (0.995 1.39) | 1.00 | 1.12 (0.92 1.36) | 1.23 (0.91 1.66) | |
| HR (95% CI)† | 1.02 (0.97 1.08) | 0.39** | 1.04 (0.87 1.25) | 1.00 | 1.05 (0.86 1.29) | 1.19 (0.88 1.61) | |
| HR (95% CI) | 1.02 (0.97 1.08) | 0.39** | 1.04 (0.87 1.25) | 1.00 | 1.05 (0.86 1.29) | 1.19 (0.88 1.61) | |
| Bladder | Cases | 670 | 227 | 271 | 142 | 30 | |
| HR (95% CI)* | 0.98 (0.93 1.04) | 0.54 | 1.00 | 1.18 (0.96 1.44) | 0.85 (0.59 1.25) | ||
| HR (95% CI)† | 0.97 (0.92 1.04) | 0.41** | 1.09 (0.89 1.32) | 1.00 | 1.08 (0.87 1.33) | 0.76 (0.51 1.13) | |
| HR (95% CI) | 0.97 (0.92 1.04) | 0.41** | 1.09 (0.89 1.32) | 1.00 | 1.08 (0.87 1.33) | 0.76 (0.51 1.13) | |
| Colorectal | Cases | 3312 | 1059 | 1512 | 556 | 185 | |
| HR (95% CI)* | 0.99 (0.96 1.02) | 0.45** | 1.07 (0.99 1.16) | 1.00 | 0.95 (0.87 1.05) | 1.05 (0.90 1.23) | |
| HR (95% CI)† | 0.99 (0.96 1.01) | 0.31** | 1.08 (0.99 1.18) | 1.00 | 0.95 (0.86 1.05) | 1.03 (0.88 1.21) | |
| HR (95% CI)e, g, f (males) | 0.98 (0.96 1.01) | 0.28** | 1.06 (0.97 1.16) | 1.00 | 0.95 (0.86 1.05) | 1.02 (0.87 1.20) | |
| Colon | Cases | 2124 | 681 | 980 | 348 | 115 | |
| HR (95% CI)* | 0.99 (0.96 1.03) | 0.63** | 1.04 (0.94 1.15) | 1.00 | 0.94 (0.83 1.06) | 1.04 (0.86 1.26) | |
| HR (95% CI)† | 0.99 (0.95 1.02) | 0.50** | 1.04 (0.93 1.15) | 1.00 | 0.93 (0.82 1.06) | 1.02 (0.83 1.24) | |
| HR (95% CI)e, g, f (males) | 0.99 (0.95 1.02) | 0.42** | 1.03 (0.92 1.14) | 1.00 | 0.93 (0.82 1.06) | 1.02 (0.83 1.25) | |
| Rectum | Cases | 1115 | 354 | 501 | 195 | 65 | |
| HR (95% CI)* | 0.98 (0.94 1.03) | 0.42** | 1.12 (0.98 1.29) | 1.00 | 0.97 (0.82 1.14) | 1.04 (0.80 1.35) | |
| HR (95% CI)† | 0.97 (0.93 1.02) | 0.28 | 1.00 | 0.97 (0.82 1.15) | 1.03 (0.79 1.35) | ||
| HR (95% CI)e, g | 0.97 (0.93 1.02) | 0.28 | 1.16 (0.999 1.36) | 1.00 | 0.96 (0.81 1.15) | 0.999 (0.76 1.32) | |
| Thyroid | Cases | 237 | 106 | 35 | 14 | ||
| HR (95% CI)* | 1.02 (0.92 1.12) | 0.76 | 1.31 (0.98 1.76) | 1.00 | 1.10 (0.75 1.61) | 1.32 (0.76 2.31) | |
| HR (95% CI)† | 1.01 (0.91 1.11) | 0.86 | 1.36 (0.99 1.87) | 1.00 | 1.08 (0.73 1.59) | 1.28 (0.73 2.25) | |
| HR (95% CI) | 1.01 (0.91 1.11) | 0.86 | 1.36 (0.99 1.87) | 1.00 | 1.08 (0.73 1.59) | 1.28 (0.73 2.25) | |
| Brain tumours | Cases | 463 | 130 | 221 | 87 | 25 | |
| HR (95% CI)* | 1.02 (0.95 1.09) | 0.62 | 0.95 (0.77 1.19) | 1.00 | 1.02 (0.79 1.31) | 0.93 (0.61 1.40) | |
| HR (95% CI)† | 1.03 (0.96 1.10) | 0.39 | 0.92 (0.72 1.17) | 1.00 | 1.03 (0.80 1.34) | 0.96 (0.63 1.47) | |
| HR (95% CI)f | 1.03 (0.96 1.10) | 0.38 | 0.92 (0.72 1.17) | 1.00 | 1.04 (0.80 1.34) | 0.97 (0.63 1.48) | |
| Haematological malignancies | Cases | 2446 | 714 | 1137 | 445 | 150 | |
| HR (95% CI)* | 1.03 (0.998 1.06) | 0.06 | 0.95 (0.87 1.05) | 1.00 | 1.02 (0.92 1.14) | 1.14 (0.96 1.36) | |
| HR (95% CI)† | 1.02 (0.99 1.05) | 0.24 | 0.95 (0.86 1.06) | 1.00 | 0.997 (0.89 1.12) | 1.11 (0.93 1.32) | |
| HR (95% CI) | 1.02 (0.99 1.05) | 0.24 | 0.95 (0.86 1.06) | 1.00 | 0.997 (0.89 1.12) | 1.11 (0.93 1.32) | |
| Non-Hodgkin’s lymphoma | Cases | 1182 | 349 | 545 | 225 | 63 | |
| HR (95% CI)* | 1.02 (0.98 1.06) | 0.37 | 0.97 (0.85 1.11) | 1.00 | 1.09 (0.94 1.28) | 1.02 (0.78 1.32) | |
| HR (95% CI)† | 1.01 (0.97 1.06) | 0.65 | 0.996 (0.86 1.15) | 1.00 | 1.07 (0.91 1.26) | 1.03 (0.79 1.34) | |
| HR (95% CI) | 1.01 (0.97 1.06) | 0.65 | 0.996 (0.86 1.15) | 1.00 | 1.07 (0.91 1.26) | 1.03 (0.79 1.34) |
*Models adjusted for age and sex (total observations = 467,656)
†Models adjusted for age, sex, ethnicity (white/other), deprivation index (quintiles), education (University degree, A-levels/HNC/HND/NVQ, GCSE/O-level/CSE, OTHER, None), fruit and vegetable intake (< 5 portions/day, ≥5 portions/day), BMI (kg/m2), height (m), smoking status (never, former light smoker [< 20 pack-years], former heavy smoker [≥20 pack-years], current light smoker [< 20 pack-years], current heavy smoker [≥20 pack-years]) and alcohol intake (never, former, current [
aAdditional site-specific covariates in the final model include use of sun/UV protection (Never/rarely/sometimes; most of the time/always; do not go out in sunshine)
bAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
cAdditional site-specific covariates in the final model include HRT use (ever used/never used), oral contraceptive use (ever used/never used), number of live births (0, 1, 2, 3+ live births), age at menarche (early menarche [< 12 years], menarche at 12–14 years, late menarche [≥15 years]), age at menopause (< 40 years, 40–44 years, 45–49 years, 50–54 years, 55–59 years, 60–64 years, ≥65 years, not had menopause/unsure), hysterectomy status (had hysterectomy, not had hysterectomy/unsure)
dAdditional site-specific covariates in the final model include diabetes at baseline (yes/no)
eAdditional site-specific covariates in the final model include diabetes at baseline (yes/no), aspirin use (regular use/non-regular use or no use), HRT use (ever used/never used; females only), red meat intake (portion/week), processed meat intake (portion/week)
fFinal model also adjusted for waist-hip ratio (> 94 cm in men, > 80 cm in women)
f(males)For cancer sites which were adjusted for different sets of covariates for males and females (colorectal, colon, rectum), this indicates that the final model for male participants was also adjusted for waist-hip ratio (> 94 cm in men)
gResults for males and females combined using meta-analysis as covariates are different
hFinal model also adjusted for family history of cancer (mother/father/sibling had cancer, no family history)
**Schoenfeld test indicated potential violation of the proportional hazards assumption (p < 0.05)